The uncontrolled proliferation of cancer cells has led to the development of small-molecule
inhibitors to target cell-cycle progression. Palbociclib, ribociclib, and abemaciclib are ATP …

Squamous cell carcinoma of the head and neck (SCCHN) is a leading cause of cancer
deaths worldwide. Epidermal growth factor receptor (EGFR), an upstream mediator of Signal …

Palbociclib is a specific inhibitor of CDK4/6 and has been shown to provide a survival
benefit in hormone receptor-positive advanced breast cancer. TCGA database reported that …

Background: Head and neck squamous cell carcinoma (HNSCC) is the fifth most common
cancer worldwide, with more than 40,000 new cases developing annually in the US alone …

EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC).
Cetuximab is a monoclonal antibody designed to interact with EGFR, block its activation …

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer
therapeutic that just recently gained Food and Drug Administration approval for treatment of …

Inhibition of the cyclin‐dependent kinase (CDK) 4/6‐retinoblastoma (RB) pathway is an
effective therapeutic strategy against cancer. Here, we performed a preclinical investigation …

Cell cycle dysregulation has been demonstrated to play an important role in the
development of cancer cell growth. Cyclin Dependent Kinases (CDK) are essential proteins …

Background Epidermal growth factor receptor (EGFR) is frequently amplified or
overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically …

Background: Melanoma, a malignancy originating in pigment-producing melanocytes, is
generally resistant to conventional treatments such as radiotherapy or chemotherapy …